Lvm Capital Management Ltdmi buys $11,252,030 stake in Amgen (AMGN)

Amgen (AMGN) : Lvm Capital Management Ltdmi scooped up 1,225 additional shares in Amgen during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 8, 2016. The investment management firm now holds a total of 69,845 shares of Amgen which is valued at $11,252,030.Amgen makes up approximately 3.23% of Lvm Capital Management Ltdmi’s portfolio.

Other Hedge Funds, Including , Ct Financial Advisors boosted its stake in AMGN in the latest quarter, The investment management firm added 550 additional shares and now holds a total of 14,481 shares of Amgen which is valued at $2,332,889. Amgen makes up approx 1.46% of Ct Financial Advisors’s portfolio.Stock Yards Bank Trust Co reduced its stake in AMGN by selling 25,379 shares or 62.44% in the most recent quarter. The Hedge Fund company now holds 15,267 shares of AMGN which is valued at $2,355,240. Amgen makes up approx 0.31% of Stock Yards Bank Trust Co’s portfolio.First Financial Bank N.a. – Trust Division boosted its stake in AMGN in the latest quarter, The investment management firm added 18 additional shares and now holds a total of 1,884 shares of Amgen which is valued at $290,645. Amgen makes up approx 0.06% of First Financial Bank N.a. – Trust Division’s portfolio.

Amgen closed down -1.44 points or -0.89% at $160.52 with 26,91,810 shares getting traded on Wednesday. Post opening the session at $162.64, the shares hit an intraday low of $160.31 and an intraday high of $162.66 and the price fluctuated in this range throughout the day.Shares ended Wednesday session in Red.

On the company’s financial health, Amgen reported $2.90 EPS for the quarter, beating the analyst consensus estimate by $ 0.29 according to the earnings call on Apr 28, 2016. Analyst had a consensus of $2.61. The company had revenue of $5527.00 million for the quarter, compared to analysts expectations of $5321.84 million. The company’s revenue was up 9.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.48 EPS.

Many Wall Street Analysts have commented on Amgen. Amgen was Initiated by Bernstein to “Mkt Perform” on Jun 29, 2016.

Amgen Inc. (Amgen) is a biotechnology company. The Company is engaged in discovering developing manufacturing and delivering human therapeutics. The Company’s sales and marketing forces are located in the United States and Europe. In the United States it sells its products to pharmaceutical wholesale distributors. The Company also markets certain products directly to consumers through direct-to-consumer print and television advertising as well as through the Internet. Outside the United States the Company sells its products to healthcare providers and/or pharmaceutical wholesale distributors. The Company’s products include Neulasta (pegfilgrastim)/NEUPOGEN (filgrastim) Enbrel (etanercept) XGEVA/Prolia (denosumab) ESAs (erythropoiesis-stimulating agents) Sensipar/Mimpara (cinacalcet) Kyprolis and Evolocumab among others.

Leave a Reply

Amgen - Is it time to Sell?

Top Brokerage Firms are advising their investors on Amgen. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.